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Correspondence332In the strictest sense, crossover to surgery in these
trials should be considered a failure of medical
therapy. If trials such as the VA study estimated
event-free survival following initial treatment, the
5-year failure rate for medical therapy would be
greater than 70%.3 Yet the trials are presented as
straightforward intent-to-treat designs, and consider
crossover to be an incidental occurrence rather than a
treatment failure. What we have learned more than
anything is that small aneurysms follow the same
trajectory as large ones. Only the rate of expansion is
different. The vast majority of them get worse, and
they have been shown (in clinical trials) not to respond
at all to medical management.4
Clinical trials, therefore, are not the appropriate best
evidence for outcome in this paradigm, because
clinical trials are not allowed to proceed to outcome.
Watchful waiting clinical trials are informed by the
observational data that underlie their conversion
rules. In this particular situation, it is an appeal to
clinical trials as the highest standard of evidence for
outcome, rather than the use of scrupulously gathered
population-based observational data, which is ‘mis-
leading and meaningless’.
Prof. Legemate’s denunciation of our article as
something that should never have been published
underscores the importance of not allowing evidence-
based doctrine to become dogma. Rather, challenges to
dogmatic thinking are exactly the reason why
controversial material must be published. We should
resist the temptation to cut every cookie mindlessly
into the same shape, but instead should think about
what study designs mean. Randomized clinical trials
are wonderful tools most of the time, and it is tempting
to argue that no observational data are ever pure
enough to inform clinical practice. But uncritical
adherence to any kind of guidelines, evidence-based
or otherwise, is a recipe for bad practice. Clinical trials
only make sense in a context in which their findings
can be applied meaningfully to the actual clinical
situation. Evaluating the effect of thoracoabdominal
aortic repair on survival compared to the natural
history of the disease is not—and will never be—one
of those contexts.
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We found the paper by Hobbs and colleagues
interesting. It provides yet more data on the risks of
peripheral vascular surgery. We have some comments
to make which might however temper their con-
clusions. The authors conclude that over a third of
their patients that underwent bypass surgery for
critical limb ischaemia sustained silent myocardial
injury. Their conclusion is based upon their findings of
elevated cardiac troponin (cTnI). They also assert that
CK-MB and ECG significantly underestimate the
incidence of myocardial injury.
Cardiac troponin is currently the preferred bio-
marker of acute myocardial infraction (MI1).1 Unfor-
tunately, elevation of cTnI can be detected in a variety
of conditions other than myocardial ischaemia.2 The
authors did not appear to exclude patients with
known causes of cTnI elevation, such as acute
coronary syndrome, myopericarditis, cardiomyopa-
thy, pulmonary embolism, heterophile antibodies,
trauma and dialysis. Indeed, recent evidence indicates
that rhabdomyolysis patients may have raised cTnI.3
Causes of rhabdomyolysis include post-operative,
Correspondence 333prolonged unconsciousness, and trauma. In this study,
none of the patients had cardiac symptoms, and we
feel that the elevated cTnI levels may have been due to
causes other than myocardial ischaemia.
False positive cTnI often causes unnecessary
anxiety and over diagnosis of myocardial infarction.
By misrepresenting the implications of cTnI elevation,
this study gives rise to a diagnostic dilemma that
could lead to a wastage of health resources, as well as
inappropriate investigations, which may cause
unnecessary morbidity. An integration of cardiac
biomarkers (CK, CKMB, cTnI), ECG and comprehen-
sive echocardiographic systolic and diastolic function
assessments (wall motion score index),4 and, if
indicated, nuclear medicine scans,5 will better identify
false positive cTnI elevations and will avoid inap-
propriate admissions to coronary care units. Clinical
context must be carefully considered before investi-
gating this group of patients for coronary artery
disease.V.S. Jeganathan*, S. Walker
Royal Hobart Hospital, Australia
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We thank Jeganathan and Walker for their interest
in our study, however, we are concerned that they
have failed to fully understand the pathophysio-
logical and prognostic significance of elevated
levels of cardiac troponin (cTn) I. Their assertion
that the results of our study must be viewed with
caution due to possible ‘false positive cTnI
elevations’ is largely unfounded. Several medical
conditions are associated with elevations in cTnI
level and the underlying mechanism is invariably
myocardial cell death. To illustrate this point, we
will take the examples provided by Jeganathan and
Walker individually:
† Acute coronary syndrome with evidence of raised
cTnI is diagnostic of myocardial injury.
† In the case of myocarditis and pericarditis, it is
active inflammation in or around the heart that
leads to myocardial necrosis and subsequent
elevation of cardiac troponin levels.1
† In moderate to severe pulmonary embolism,
elevated cTnI levels occur in approximately one
in seven patients and are believed to be a
consequence of myocardial damage secondary to
an acute rise of right ventricular afterload and
systemic hypoxemia.2
† In subjects with end stage renal failure (ESRF)
requiring dialysis elevated cardiac troponin levels
are thought to be due to a combination of uraemic
myocarditis and cardiac micro-infarctions as well
as impaired renal excretion.3 Elevations in cTnI,
however, are uncommon as demonstrated by a
large series of 733 subjects with ESRF where only
0.4% were shown to have cTnI levels at a level
diagnostic of myocardial injury.4 None of the
subjects in our study had ESRF.
† The absence of cTnI in foetal and healthy or
diseased adult skeletal muscle5 implies that elev-
ated levels of cTnI do not occur as a result of
rhabdomyolysis. Furthermore, cTnI has been
demonstrated to be a valuable biomarker for the
detection of sub-clinical myocardial damage inEur J Vasc Endovasc Surg Vol 30, September 2005
